



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

1 21 January 2021
2 EMA/557461/2020
3 Veterinary Medicines Division

4 **EU Implementation Guide (IG) on veterinary medicines**
5 **product data in the Union Product Database**

6 Implementation of the requirements of Regulation (EU) 2019/6 for the Union
7 database on veterinary medicinal products

8 Chapter 4: Process and format for the submission of legacy data on
9 veterinary medicinal products

10 Version 1

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



11 **Table of contents**

12 Scope of this guidance..... 3

13 1. Systems to submit legacy veterinary medicinal product data 3

14 2. Mapping of terminologies – User Guidance 4

15 2.1. Identifying the data and mapping approach..... 4

16 2.2. Data mapping..... 5

17 2.3. Data transformation and enrichment 5

18 2.4. Submit change requests 5

19 2.5. Define synchronisation approach..... 5

20 2.6. Practical considerations for RMS data mapping 6

21 2.7. Practical considerations for OMS data mapping 7

22 2.8. Practical considerations for SMS data mapping 8

23 3. Veterinary medicinal product legacy data - User guidance 9

24 Annex I – SPOR Reference Documents 21

25

26 **Scope of this guidance**

27 This document provides detailed guidance on the steps and the data elements for the submission of
28 legacy medicinal products authorised for veterinary use to the UPD.

29 The EU Implementation Guide on veterinary medicines product data in the Union Product Database
30 (Vet EU IG) Chapter 2 on the Format for the electronic submission of veterinary medicinal product
31 information describes the business rules, data fields and specification for the creation of the complete
32 record of a new veterinary medicinal product in the context of regulatory entitlements after 28 January
33 2022.

34 This text, Chapter 4 of the Vet EU IG, provides guidance on the mapping of the underlying terminology
35 and lists the data elements required for the submission of legacy data on veterinary medicinal products
36 that shall be submitted in UPD by 28 January 2022.

37 For the purpose of this chapter, *legacy data* is defined as any data on a veterinary medicinal product
38 authorised in a Member State before 28 January 2022.

39 The following aspects, as outlined in the Vet EU IG Chapter 2, apply also to the legacy data
40 submission:

- 41 • The scope of the veterinary medicinal products to be provided in accordance with the provisions
42 laid down in Articles 55 and 102 of Regulation (EU) 2019/6;
- 43 • The defining characteristics of a veterinary medicinal product that enable the unique identification
44 of a product record by assigning the UPD product ID, permanent ID and package ID;
- 45 • The confidentiality arrangements conforming to Article 56 of Regulation (EU) 2019/6;
- 46 • The information model for veterinary medicinal products into the UPD, which is based on the [SPOR](#)
47 [API Technical specification](#) and [HL7 FHIR specification](#), and also described in Chapter 5 on the
48 Technical Specification;
- 49 • The format, business guidance and conventions outlined in Chapter 2 of the Vet EU IG on the data
50 elements that fall under the scope of legacy data submission into the UPD.

51 **1. Systems to submit legacy veterinary medicinal product** 52 **data**

53 In the context of the submission of legacy data on veterinary medicinal products, the following
54 solutions are available, as described in Chapter 1 of the Vet EU IG:

- 55 • an application programming interface (API)
- 56 • the UPD user interface (UI);
- 57 • ad-hoc temporary file upload.

58 As a temporary supporting measure to the initial upload of legacy data, the Agency will accept XML
59 file(s) fully compatible with FHIR format and SPOR terminologies that may be produced in-house by
60 NCAs. The XML file(s) shall be created based on the specifications defined in Chapter 5 of the Vet EU
61 IG (i.e. API and FHIR message specifications). The completed XML file(s) shall be sent to the EMA
62 service desk for upload into the UPD system.

63 NOTE 1: Should the XML file or any part of it (i.e. terminologies used) be recognised as not being
64 compatible with the requirements when uploaded into the UPD system, the Agency will notify the NCAs
65 and reject such submission.

66 NOTE 2: The Agency has the capacity to upload XML File(s) only once for each NCA. Therefore, this
67 service shall be considered a temporary supporting measure and will be available only once and at the
68 time of the legacy data provision by the NCAs before January 2022. The NCAs therefore need to
69 prepare for the long-term submission strategy and adapt in-house systems accordingly.


70 **2. Mapping of terminologies – User Guidance**

71 This section describes the procedure to map the so-called “UPD underlying terminologies”. UPD
72 underlying terminologies refer to the Referentials, Organisations and Substance master data contained
73 within the SPOR data management system at EMA. Regardless of the method that will be used to
74 submit veterinary medicinal product data into the UPD, the competent authority should align and map
75 the nationally employed terminologies to the SPOR data, i.e. the UPD underlying terminologies, prior to
76 the submission of the veterinary medicinal product data into the UPD.

77 Data mapping is the process of matching data objects between two (or more) distinct sets of data.
78 Mapping and matching the underlying data (i.e. Referentials, Organisations and Substance data)
79 against SPOR terminology is a pre-condition for competent authorities and marketing authorisation
80 holders to fulfil the legal obligation not only for the initial legacy data provision but also, beyond 28
81 January 2022, to enable maintenance of the data in UPD.

82 The approach here described is proposed for mapping and matching the nationally employed
83 terminologies against the SPOR systems, however, it does not require or oblige any stakeholders to
84 implement this approach in their in-house systems.

85 Once all the registration requirements in the SPOR system as described in the Vet EU IG Chapter 1
86 have been fulfilled, the steps shown below should be followed:



87

88 **2.1. Identifying the data and mapping approach**

89 As a first step, all veterinary medicinal products which fall within the scope of the submission of data in
90 UPD in accordance with provisions laid down in Articles 55 and 102 of Regulation (EU) 2019/6 and as
91 detailed in the Vet EU IG Chapter 2 should be identified.

92 **Repository:** where do Referential, Organisation and Substance data reside in the national in-house
93 systems;

94 **Type:** determine whether the Referential, Organisation and Substance data in the in-house system is
95 structured or unstructured (i.e. Access Database, CSV, XML, pdf), codified (i.e. uses codes as
96 identifiers), translated between languages;

97 **Quality:** understand whether quality control processes are in place and data quality resources
98 dedicated to managing data are available;

99 **Volume and stability:** determine the quantity of underlying data to be managed and the frequency of
100 the data update and refresh.

101 The above aspects could guide on the approach to be pursued for the initial data mapping and may
102 support in the identification of the efforts and resources required to carry out mapping and the
103 identification of areas where a level of automation can be utilised.

104 **2.2. Data mapping**

105 This step entails the identification of what data elements need mapping (against RMS, OMS and SMS)
106 and develop the process for how to undertake the mapping in line with your initial data mapping
107 approach (e.g. manual or semi-automated). Whilst human intervention may still be required to verify
108 data matches, each organisation will have a very different data profile and will require mapping tools,
109 more or less advanced, appropriate to their own data requirements.

110 EMA can only provide guidance on processes but will not be providing any data mapping tools.

111 **2.3. Data transformation and enrichment**

112 The mapping process should highlight any structural differences between your local source data and
113 the SPOR master data. In order to submit changes/updates, the relevant data may need to be
114 structured in line with SPOR data by means of the following actions:

- 115 • **Data transformation:** if a change in the data structure is foreseen e.g. split data values if a term
116 in the national database can be mapped to 2 term IDs based on the RMS terminologies;
- 117 • **Data enrichment:** if missing data require enrichment and completion e.g. add new data such as
118 'post code'.

119 **2.4. Submit change requests**

120 The mapping process should highlight any discrepancies or gaps between the local data source and the
121 data available in the SPOR databases. Any necessary missing terms shall be requested to be added in
122 SPOR whilst terms which require amendment(s) shall be submitted as proposed updates. This should
123 be done via a change request to EMA via the SPOR portal for RMS or OMS change requests or via the
124 EMA Service Desk for SMS change requests. The local data source should be amended/mapped in line
125 with the outcomes of the applicable change requests.


126 **2.5. Define synchronisation approach**

127 Following the initial data mapping and matching, it is advisable that a strategy for the future data
128 synchronisation is defined determining how to prospectively maintain data synchronisation with RMS,
129 OMS and SMS. The steps outlined in sections 2.1. to 2.4. may enable the definition of such strategy.
130 The possible solution may entail a simple manual process, or a more automated solution based on the
131 volume and the stability of the data. Frequency of data updates should be considered to determine
132 whether a continuous data synchronisation processes is preferable vis a vis a periodic batch of changes
133 and also what the consequences might be if an automatic solution is chosen.

134 The synchronisation approach may be adapted and further developed as more experience, complete
135 view of the processes and systems is gathered.

136 **2.6. Practical considerations for RMS data mapping**

137 The figure below summarises the advisable steps to be followed for the mapping of the local data with
138 the RMS solution.



139

140 The following is to be considered when mapping referentials:

- 141 • Should the applicable RMS lists not include translations: if the term name in English is provided the
142 applicable RMS ID shall be used. NCAs can upload missing translations either manually or via bulk
143 upload as detailed in section 3.8 of the RMS Web User Manual, available on the [SPOR website](#)
144 under 'Help'.
- 145 • Additional documentation related to RMS is available in Annex I – SPOR Reference Documents.


146 The complete list of RMS lists to be mapped (list identifiers are available in the relevant section of
147 Chapter 2):

- 148 • Anatomical Therapeutic Chemical Classification system - veterinary
- 149 • Application legal basis
- 150 • Combination package
- 151 • Combined pharmaceutical dose form
- 152 • Combined Term
- 153 • Contact Party Role
- 154 • Country
- 155 • Domain
- 156 • EU Regulatory Authorisation Procedure
- 157 • Language
- 158 • Legal status for the supply

- 159 • Manufacturing Activity
- 160 • Medicinal Product Name Part Type
- 161 • Pharmaceutical dose form
- 162 • Product cross reference type
- 163 • Product information document type
- 164 • Regulatory entitlement status
- 165 • Regulatory entitlement type
- 166 • Routes and Methods of Administration
- 167 • Target Species
- 168 • Units of Measurement
- 169 • Units of Presentation

170 **2.7. Practical considerations for OMS data mapping**

171 The figure below summarises the advisable steps to be followed for the mapping of the local data with
172 the OMS solution.




173
174 The following features are to be considered when accessing the OMS web-portal:

- 175 • The browsing of the OMS list (dictionary)
- 176 • The OMS content allows for search based on Organisation and Organisation Location IDs,
177 Organisation names and address data (the role of the organisation is not stored in OMS)

- 178 • OMS CSV file can be downloaded (without history) for the entire content of OMS
 179 Organisations/Locations with Status Active & Inactive and for individual search result (list with
 180 Organisations/Locations)
- 181 • Marketing Authorisation Holders should ensure that all organisation data (addresses) for products
 182 under their responsibility are recorded in OMS and that records are up to date and complete.
- 183 Additional documentation related to OMS solution is available in Annex I – SPOR Reference Documents.

184 **2.8. Practical considerations for SMS data mapping**

185 The figure below summarises the advisable steps to be followed for the mapping of the local data with
 186 the substance list that will be available in the SMS solution.



187

188 The following is to be considered when mapping substance names:

- 189 • SMS provides the list of substances names and IDs and does not include any information on how
 190 the substances are used within veterinary medicinal products. The role of the substance will be
 191 specified only in the context of the veterinary medicinal product, i.e. in UPD.
- 192 • Both CSV & XML files can be downloaded from EUTCT
- 193 • For Veterinary vaccines and proteins substances, the EUTCT lists do not currently include
 194 translations: if the substance name in English is provided for the relevant substance, the EUTCT ID
 195 shall be used to provide the veterinary product information in UPD. Meanwhile, a change request to
 196 update the existing substance ID shall be provided via the EMA Service Desk portal to submit the
 197 missing translation(s).

198 Additional documentation related to SMS solution is available in Annex I – SPOR Reference Documents.

199 NOTE: At present, veterinary substances are undergoing cleansing in SMS. This is expected to be
 200 completed by end January 2021 at the latest. Once completed, the cleaned Substance data will be

201 uploaded to SMS and automatically synchronised with EUTCT. NCAs have access to substance list via
202 EUTCT only (and in future SMS access will be provided) which is a (real time) view of what is in SMS.
203 NCAs should map their substance data to EUTCT once the data cleansing is completed. Substance
204 data, especially for immunologicals, is very variable between and within NCA databases, because of the
205 complexity of the substances and the different practices in identifying immunologicals by MAH and
206 NCAs over time. Specifically, NCAs may identify the substance based on different levels of complexity
207 and information which may also be handled in a structured or in unstructured way. In performing the
208 mapping, the NCA should identify, map and record the national substance term to the EUTCT
209 substance ID which refers to the most relevant, appropriate and correct level of information. As a long-
210 term plan, EU-SRS will be synchronised with SMS, loaded with all EU substances and further structured
211 scientific data-fields will be added, however, neither the Substance name nor the Substance ID will
212 change in SMS. Therefore, the initial mapping that will be performed by NCAs in preparation of the
213 Legacy data upload in UPD will stand correct and no further mapping action are foreseen on substance
214 terminology.

215 Example:

- 216 • SMS ID: 300000025059
- 217 • Preferred term in SMS: Actinobacillus pleuropneumoniae, serotype 2, strain App2TR98, Inactivated
- 218 • Preferred term in EU-SRS: Actinobacillus pleuropneumoniae, serotype 2, strain App2TR98,
219 Inactivated
- 220 • Organism (EU-SRS only data field): Actinobacillus pleuropneumoniae
- 221 • Serotype (EU-SRS only data field): serotype 2
- 222 • Strain (EU-SRS only data field): strain App2TR98

223 **3. Veterinary medicinal product legacy data - User guidance**

224 This section outlines the data elements that fall within the scope of the submission of the legacy data
225 on veterinary medicinal product in UPD.

IA Annex	EU Vet IG Chapter 2 Ref.	Data element name	FHIR Path	SPOR list name	Mandatory for Legacy Data	Conformance in Chapter 2	European/National	Note applicable to Legacy Data
Class	1	Veterinary medicinal product	MedicinalProductDefinition		yes	Mandatory	European	
1.1	1.1	Domain	MedicinalProductDefinition.domain	Domain	yes	Mandatory	European	
3.7	1.3	(Authorised) pharmaceutical form	AdministrableProductDefinition.administrableDoseForm and/ or MedicinalProductDefinition.combinedPharmaceuticalDoseForm	Combined Term Pharmaceutical dose form Combined pharmaceutical dose form Combination package	yes	Conditional (at least one form based on the 4 lists should be provided)	European	
3.16	1.4	Legal status of supply	MedicinalProductDefinition.legalStatusOfSupply	Legal status for the supply	yes	Conditional (either at MP level or at Pack)	National	
Class	1.6	Product Classification			yes		European	
4.7	1.6.1	Legal basis	RegulatedAuthorization.basis	Application legal basis	yes	Mandatory	European	

IA Annex	EU Vet IG Chapter 2 Ref.	Data element name	FHIR Path	SPOR list name	Mandatory for Legacy Data	Conformance in Chapter 2	European/National	Note applicable to Legacy Data
3.9	1.6.2	ATC vet code(s)	MedicinalProductDefinition.classification	Anatomical Therapeutic Chemical Classification system - veterinary	yes	Conditional (either at MP level or at Pack)	European	
3.9	1.6.3	ATC vet code(s) flag	MedicinalProductClassification.atcPending		yes	Conditional	European	
Class	1.7	Veterinary medicinal product name			yes	Mandatory	European & National	
1.3	1.7.1	Full name	MedicinalProductDefinition.name.productName		yes	Mandatory	European & National	
	1.7.2	Type	MedicinalProductDefinition.name.type	Medicinal Product Name Part Type	yes	Mandatory	European & National	
Class	1.7.3	Country/Language			yes	Mandatory	European & National	
	1.7.3.1	Country	MedicinalProductDefinition.name.countryLanguage.country	Country	yes	Mandatory	European & National	
	1.7.3.2	Language	MedicinalProductDefinition.name.countryLanguage.language	Language	yes	Mandatory	European & National	

IA Annex	EU Vet IG Chapter 2 Ref.	Data element name	FHIR Path	SPOR list name	Mandatory for Legacy Data	Conformance in Chapter 2	European/National	Note applicable to Legacy Data
Class	1.9	Contact (QPPV)			yes	Mandatory	European	
3.13	1.9.1	Identifier	MedicinalProductDefinition.contact.contact(PractitionerRole).identifier		yes	Mandatory	European	
	1.9.2	Role	MedicinalProductDefinition.contact.type	Contact Party Role	yes	Mandatory	European	
3.14	1.9.3	Location	tbd	OMS	yes	Mandatory	European	
Class	1.10	Attached Document			yes		European & National	
1.7	1.10.1	(Attached document) identifier (master)	DocumentReference.masterIdentifier (referenced from MedicinalProductDefinition.AttachedDocument)		yes	Mandatory	European & National	
1.7	1.10.2	(Attached document) status	DocumentReference.status		yes	Mandatory	European & National	

IA Annex	EU Vet IG Chapter 2 Ref.	Data element name	FHIR Path	SPOR list name	Mandatory for Legacy Data	Conformance in Chapter 2	European/National	Note applicable to Legacy Data
1.7	1.10.3	(Attached document) type	DocumentReference.type	Product information document type	yes	Mandatory	European & National	
1.7	1.10.4	(Attached document) content type	DocumentReference.attachment.contentType		yes	Mandatory	European & National	
1.7	1.10.5	(Attached document) language	DocumentReference.attachment.language	Language	yes	Mandatory	European & National	
1.7	1.10.6	(Attached document) content	DocumentReference.attachment.data		yes	Mandatory	European & National	
1.7	1.10.7	(Attached document) title	DocumentReference.attachment.title		yes	Mandatory	European & National	
1.7	1.10.8	(Attached document) related medicinal products	DocumentReference.extension.related		yes	Mandatory	European & National	
Class	1.11	Product cross-reference			yes	Conditional	European & National	For parallel traded Product only

IA Annex	EU Vet IG Chapter 2 Ref.	Data element name	FHIR Path	SPOR list name	Mandatory for Legacy Data	Conformance in Chapter 2	European/National	Note applicable to Legacy Data
4.9, 4.10	1.11.1	Product cross-reference type	MedicinalProductDefinition.crossReference.type	Product cross reference type	yes	Mandatory	European & National	
	1.11.2	Reference product Identifier	MedicinalProductDefinition.crossReference.productReference		yes	Mandatory	European & National	
	1.11.3	Source product identifier	MedicinalProductDefinition.crossReference.productReference	UPD ID	yes	Mandatory	National	
Class	1.12	Manufacturing Business Operation			yes	Mandatory	European & National	only for batch release
1.6	1.12.1	Manufacturer	MedicinalProductDefinition.manufacturingBusinessOperation.manufacturer	OMS	yes	Mandatory	European & National	only for batch release
1.6	1.11.2	Manufacturing activity	MedicinalProductDefinition.manufacturingBusinessOperation.type	Manufacturing Activity	yes	Mandatory	European & National	only for batch release
Class	2	Authorisation /registration/ entitlement information			yes	European & National	European & National	

IA Annex	EU Vet IG Chapter 2 Ref.	Data element name	FHIR Path	SPOR list name	Mandatory for Legacy Data	Conformance in Chapter 2	European/National	Note applicable to Legacy Data
1.2	2.1	Authorisation/registration/entitlement type	RegulatedAuthorization.type	Regulatory entitlement type	yes	Mandatory	European	
4.8	2.2	Authorisation/registration/entitlement number	RegulatedAuthorization.identifier.value		yes	Conditional	National	
4.4	2.3	Country	RegulatedAuthorization.region	Country	yes	Mandatory	National	
3.3	2.4	Reponsible authority (organisation)	RegulatedAuthorization.holder	OMS	yes	Mandatory	National	
3.4	2.5	Authorisation status	RegulatedAuthorization.status	Regulatory entitlement status	yes	Mandatory	National	
4.3	2.7	Marketing authorisation date	RegulatedAuthorization.relatedDate.dateTime		yes	Mandatory	National	
3.3	2.9	Product Owner (organisation)	RegulatedAuthorization.holder	OMS	yes	Mandatory	National	
6.1	2.10	Source wholesale distributor (organisation)	RegulatedAuthorization.parallelTradeSourceWholesaler	OMS	yes	Conditional	National	For parallel traded Product only
6.2	2.10	Destination wholesale distributor (organisation)	RegulatedAuthorization.parallelTradeDestinationWholesaler	OMS	yes	Conditional	National	For parallel traded Product only
4.5	2.11	Reference member state	RegulatedAuthorization.country	Country	yes	Conditional	European	

IA Annex	EU Vet IG Chapter 2 Ref.	Data element name	FHIR Path	SPOR list name	Mandatory for Legacy Data	Conformance in Chapter 2	European/National	Note applicable to Legacy Data
			ase.referenceCountry					
4.6	2.12	Concerned member state	RegulatedAuthorization.case.concernedCountries	Country	yes	Conditional	European	
Class	2.13	Marketing authorisation procedure			yes	Mandatory	European	
4.2	2.13.1	Procedure number	RegulatedAuthorization.case.identifier		yes	Mandatory	European	
3.2 or 3.1?	2.13.2	Product Identifier	RegulatedAuthorization.case.identifier	TBC	yes	Conditional	European	
4.1	2.13.3	Procedure type	RegulatedAuthorization.case.type	EU Regulatory Authorisation Procedure	yes	Mandatory	European	
Class	3	Pharmaceutical Product			yes	Mandatory	European	
3.6	3.1	Route of administration	AdministrableProductDefinition.routeOfAdministration.code	Routes and Methods of Administration	yes	Mandatory	European	
3.8	3.2	Target species	AdministrableProductDefinition.routeOfAdministration.targetSpecies.code	Target Species	yes	Mandatory	European	
Class	3.3	Withdrawal period			yes	optional	European	Only as a free text

IA Annex	EU Vet IG Chapter 2 Ref.	Data element name	FHIR Path	SPOR list name	Mandatory for Legacy Data	Conformance in Chapter 2	European/National	Note applicable to Legacy Data
3.1	3.3.3	Note	AdministrableProductDefinition.routeOfAdministration.targetSpecies.withdrawalPeriod.supportingInformation		yes	optional	European	
Class	4	Ingredient			yes	Mandatory	European	
1.4 or 1.5	4.1	Ingredient role	Ingredient.role		yes	Mandatory	European	
Class	4.3	Substance			yes	Mandatory	European	
1.4	4.3.1	Substance	Ingredient.substance.codeCodeableConcept	SMS	yes	Mandatory	European	
	4.3.2	Strength			yes	Conditional	European	
Class	4.3.2	Strength (quantitative composition)			yes	Conditional	European	
1.5	4.3.2	Strength (presentation) - numerator	Ingredient.substance.strength.presentation.numerator	Units of Measurement	yes	Conditional	European	
1.5	4.3.2	Strength (presentation) - denominator	Ingredient.substance.strength.presentation.denominator	Units of Presentation	yes	Conditional	European	
1.5	4.3.2	Strength (concentration) - numerator	Ingredient.substance.strength.concentration.numerator	Units of Measurement	yes	Conditional	European	

IA Annex	EU Vet IG Chapter 2 Ref.	Data element name	FHIR Path	SPOR list name	Mandatory for Legacy Data	Conformance in Chapter 2	European/National	Note applicable to Legacy Data
			centration.numerator					
1.5	4.3.2	Strength (concentration) - denominator	Ingredient.substance.strength.concentration.denominator	Units of Measurement	yes	Conditional	European	
Class	4.3.3	Reference Strength			yes	optional	European	
	4.3.3	Reference Substance	Ingredient.substance.strength.referenceStrength.substanceCodeableConcept	SMS	yes	Conditional	European	
1.5	4.3.3	Reference strength (presentation) - numerator	Ingredient.substance.strength.referenceStrength.strength.numerator	Units of Measurement	yes	Conditional	European	
1.5	4.3.3	Reference strength (presentation) - denominator	Ingredient.substance.strength.referenceStrength.strength.denominator	Units of Presentation	yes	Conditional	European	
1.5	4.3.3	Reference strength (concentration) - numerator	Ingredient.substance.strength.referenceStrength.strength.numerator	Units of Measurement	yes	Conditional	European	

IA Annex	EU Vet IG Chapter 2 Ref.	Data element name	FHIR Path	SPOR list name	Mandatory for Legacy Data	Conformance in Chapter 2	European/National	Note applicable to Legacy Data
1.5	4.3.3	Reference strength (concentration) - denominator	Ingredient.substance.strength.referenceStrength.strength.denominator	Units of Measurement	yes	Conditional	European	
3.1	5	Permanent identifier	MedicinalProductDefinition.id		yes	Conditional	National	
Class	6	Packaged medicinal product			yes	Mandatory	European & National	
3.15	6.1	Package description	PackagedProductDefinition.description		yes	Mandatory	European & National	
3.15	6.1.1	Language	PackagedProductDefinition.description.valueCode	Language	yes	Mandatory	European & National	
3.15	6.1.2	Country	MedicinalProductDefinition.name.countryLanguage.country	Country	yes	Mandatory	European & National	
3.15.	6.2	Pack Size (structured values)	PackagedProductDefinition		yes	Mandatory	European	
	6.3	Package identifier	PackagedProductDefinition.identifier		yes	Conditional	European	
3.16	6.4	Legal status of supply	PackagedProductDefinition.legalStatusOfSupply	Legal status for the supply	yes	Conditional	National	Only if applicable to package level

IA Annex	EU Vet IG Chapter 2 Ref.	Data element name	FHIR Path	SPOR list name	Mandatory for Legacy Data	Conformance in Chapter 2	European/National	Note applicable to Legacy Data
Class	6.5	Marketing authorisation (package level)			yes	Conditional	National	Only if applicable to package level
	6.5.1	Marketing authorisation number (package level)	RegulatedAuthorization.identifier		yes	Mandatory	National	Only if applicable to package level

227

Annex I – SPOR Reference Documents

The following reference documents are accessible from the [SPOR portal](#):

- OMS/RMS web user manual – guidance on SPOR services, e.g. searching, exporting data, requesting CRs
- SPOR user registration manual (how to register for SPOR)
- SPOR affiliation template (to register the first industry super user)
- Change Request (CR) Validation in OMS
- Organisation data quality standards in OMS
- SPOR SLAs (SLA are indicative and will be reviewed in future)

The RMS & OMS training videos are available to view on the [@emainfo](#) youtube channel

- RMS operating model document ([link](#))
- OMS operating model document ([link](#))

Recordings of the NCA webinars on RMS and OMS are available on EU NTC.